More Positive Data For Recordati Cushing's Drug
Isturisa Could Become A Big Earner
With Isturisa, licensed last year from Novartis, it seems as though the Italian drugmaker has got hold of a therapy that could become lucrative, as well as highly effective for Cushing's disease.
You may also be interested in...
Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird
Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."